跳轉至內容
Merck
全部照片(1)

文件

S5637

Sigma-Aldrich

磺胺二甲基嘧啶 钠盐

≥98%

同義詞:

4-氨基-N-(4,6-二甲基-2-嘧啶基)苯磺酰胺

登入查看組織和合約定價


About This Item

線性公式:
C12H13N4O2SNa
CAS號碼:
分子量::
300.31
EC號碼:
MDL號碼:
分類程式碼代碼:
51284910
PubChem物質ID:
NACRES:
NA.85

品質等級

化驗

≥98%

形狀

powder

儲存條件

(Keep container tightly closed in a dry and well-ventilated place.)

顏色

white to off-white

溶解度

H2O: soluble 50 mg/mL

抗生素活性譜

Gram-negative bacteria
Gram-positive bacteria

作用方式

DNA synthesis | interferes
enzyme | inhibits

儲存溫度

2-8°C

SMILES 字串

[Na].Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1

InChI

1S/C12H14N4O2S.Na.H/c1-8-7-9(2)15-12(14-8)16-19(17,18)11-5-3-10(13)4-6-11;;/h3-7H,13H2,1-2H3,(H,14,15,16);;

InChI 密鑰

WIVZAHIZHZEEOX-UHFFFAOYSA-N

一般說明

化学结构:磺胺

應用

磺胺二甲嘧啶是一种抗生素,在临床上用于治疗支气管炎、前列腺炎和尿路感染。用于处置和消除动力学研究。其用于开发液体(如牛奶、蜂蜜和猪尿)中的定量检测技术

生化/生理作用

磺胺二甲嘧啶是一种抗微生物性硫药,通过抑制二氢喋呤合成酶而阻断二氢叶酸的合成。磺胺二甲嘧啶是细菌合成叶酸所需的对氨基苯甲酸 (PABA) 的竞争性抑制剂。诱导 CYP3A4 表达并被 N-乙酰转移酶乙酰化。它表现出性别依赖性药代动力学,由男性特有的 CYP2C11 亚型代谢。磺胺二甲嘧啶具有抑菌作用。

包裝

25G,100G

其他說明

保存于密闭容器内,置于干燥通风处。

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Oral

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Bożena Czubat et al.
Frontiers in microbiology, 11, 2008-2008 (2020-09-26)
MSMEG_4305 is a two-domain protein of Mycolicibacterium smegmatis (Mycobacterium smegmatis) (Mycolicibacterium smegmatis). The N-terminal domain of MSMEG_4305 encodes an RNase H type I. The C-terminal domain is a presumed CobC, predicted to be involved in the aerobic synthesis of vitamin
Tangbin Yang et al.
Hybridoma (2005), 29(5), 403-407 (2010-11-06)
A specific monoclonal antibody (MAb) against sulfamethazine was produced with hybridoma technology. This assay shows very high sensitivity with IC50 of 0.4 ng/mL and LOD of 0.05 ng/mL when it was run in 0.02 mol/L PBS (pH 7.5). This MAb has shown high
C J Chapron et al.
Journal of clinical pharmacology, 16(7), 338-344 (1976-07-01)
The relationship between sulfamethazine disposition kinetics and acetylation phenotype was studied in man. Sulfamethazine pharmacokinetic parameters were determined after the administration of the drug as an oral suspension. When the half-life, acetylation rate constant, or per cent available dose excreted
A D Mitchell et al.
Drug metabolism and disposition: the biological fate of chemicals, 14(2), 161-165 (1986-03-01)
Swine weighing 60-70 kg were orally administered 14C-sulfamethazine [4-amino-N-(4,6-dimethyl-2-pyrimidinyl)benzene[U-14C]sulfonamide] at 12-hr intervals for 7 days (165 mg/dose; 0.126-5.04 mCi/mmol). The animals were sacrificed at 8 hr or 2, 5, or 10 days after the last dose was given and tissues
Craig Knox et al.
Nucleic acids research, 39(Database issue), D1035-D1041 (2010-11-10)
DrugBank (http://www.drugbank.ca) is a richly annotated database of drug and drug target information. It contains extensive data on the nomenclature, ontology, chemistry, structure, function, action, pharmacology, pharmacokinetics, metabolism and pharmaceutical properties of both small molecule and large molecule (biotech) drugs.

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務